Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer

NCT01472783 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT01472783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01472783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer
Lead sponsor
Vejle Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2011
Completion date
August 31, 2016
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent, epithelial ovarian cancer